Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250003/S011

Embrace Hydrogel Embolic System

Instylla, Inc. · Decision date Oct 23, 2026

MEDTECHLEDGER EXPLANATIONP250003/S011

What did the FDA approve?

The FDA record shows an approval decision dated 2026-10-23 for P250003/S011, a Special (Immediate Track) supplement to PMA P250003 held by Instylla, Inc. for the Embrace® Hydrogel Embolic System, device category Embolization Agent, Vascular, product code QVG. The stated purpose is approval for new marketing material for Embrace HES, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier.

The identifier links S011 to the original P250003 approval, so this action amends that file rather than approving the system anew. The record does not specify which manufacturing element changed or what the marketing material contains, and the stated purpose of the material is not independent evidence of safety or clinical effectiveness.

The record contains no information on the specific process change, the material's content or claims, or any clinical data.

FDA approval order statement

Approval for new marketing material for Embrace HES.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Oct 23, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250003/S011
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
APPR
Decision date
Oct 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250003 · Original PMA

    Embrace(TM) Hydrogel Embolic System

  2. P250003/S009 · Related supplement

    Embrace Hydrogel Embolic System

  3. P250003/S011 received

    Application receipt date recorded by FDA.

  4. P250003/S010 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  5. P250003/S008 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  6. P250003/S011 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250003

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA approvalAug 5, 2025FDA
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Instylla, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records